国家药监局：要针对冬季呼吸道疾病多发态势，加强有关重点药品的监管力度

Core Viewpoint - The National Medical Products Administration (NMPA) emphasizes the importance of enhancing drug regulation in 2024, focusing on creating a transparent and predictable regulatory environment to support pharmaceutical innovation and contribute to national economic development [1] Group 1: Drug Safety and Regulation - The NMPA aims to improve drug safety assurance levels and establish a robust drug safety responsibility system, including a regular risk consultation mechanism to address risks at an early stage [1] - There is a commitment to strengthen the regulation of key drugs, especially in light of the increased incidence of respiratory diseases during winter [1] Group 2: Support for Pharmaceutical Industry - The NMPA plans to enhance the quality and efficiency of drug review and approval processes, implementing tailored strategies for key products and supporting the development of innovative drugs and medical devices [1] - The agency will promote the coordinated development of the "three medical" sectors (medical insurance, medical care, and pharmaceuticals) and ensure the quality and efficacy consistency of generic drugs according to international standards [1] Group 3: Regulatory System and Capacity Building - There is a focus on strengthening the regulatory system and capacity, improving the legal and standard framework, and advancing smart regulation and regulatory science to modernize drug regulation [1] - The NMPA is tasked with planning key work for the upcoming year to ensure the successful completion of the 14th Five-Year Plan and a strong start to the 15th Five-Year Plan [1]